Prognostic factors and specific populations in the pharmacogenetic randomized phase II trial of FOLFIRI with high-dose (HD) of irinotecan vs standard doses in metastatic colorectal cancer (mCRC) patients (pts) according to UGT1A1 genotype

Authors :: D. Paez
M. Martín
Pau Riera
Anna C. Virgili
Juliana Salazar
L. Cirera
Ivana Sullivan
A. Sebio Garcia
Maria Tobeña
Julen Fernandez-Plana
Source :: Annals of Oncology. 28:v180
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Colorectal cancer
Hematology
medicine.disease
Irinotecan
Internal medicine
Genotype
FOLFIRI
Medicine
business
Pharmacogenetics
medicine.drug

Full Text Access

Tools